Is NCT07270237 recruiting in Middletown, NJ?

Yes, NCT07270237 is currently recruiting participants at its Middletown, NJ location. This pancreatic cancer clinical trial is actively enrolling qualified participants.

How do I join the pancreatic cancer clinical trial in Middletown?

To join this clinical trial in Middletown, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Middletown clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Pancreatic Cancer Clinical Trial in Middletown, NJ

About This Pancreatic Cancer Study in Middletown

The researchers are doing this study to see how well a type of ultrasound imaging called multiparametric ultrasound (mpUS), can be used to examine, evaluate, and provide information about different cancerous and non-cancerous tissue. The researchers will compare the results of mpUS imaging to standard ultrasound imaging and other standard tests. mpUS imaging is a type of ultrasound imaging that combines different ultrasound methods and analysis to create a more detailed and accurate assessment of tissue. Standard ultrasound provides a basic image of tissue structure, but mpUS imaging can also show blood vessels, blood flow, and detailed tissue structure (microstructure). The researchers think that mpUS may be a better way for evaluating cancer because it combines different ultrasound methods to assess tissue.

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Cohort 1 - Feasibility of multiparametric endoscopic ultrasound (mpEUS) imaging of patients at high-risk for pancreatic cancer: Patient Group: those having standard endoscopic ultrasounds because they are at high risk of pancreatic cancer Participants enrolled into the Memorial Sloan Kettering Cancer Center Pancreatic Registry protocol (IRB#: 02-102) will be eligible for this study. Specifically, related individuals without pancreatic cancer who are at-risk for developing pancreatic cancer and meet all of the following criteria (family health history will be self-reported):

10 years younger than the earliest pancreatic cancer diagnosis in the family

Be at least 50 years old

Be at least 40 years old if diagnosed with FAMMM syndrome (CDKN2A/p16) or Hereditary Pancreatitis (PRSS1, SPINK1/PST1, CTRC, CPA1 or other candidate hereditary pancreatitis genes)

Be at least 35 years old if diagnosed with Peutz-Jeghers syndrome (STK11 aka LKB1)

Not pregnant and not Nursing

Relatives at least 21 years old with other high-risk clinical criteria that warrants pancreatic cancer surveillance or follow-up as determined by the project leader (Dr. Vineet Rolston)

Must agree to be contacted for follow-up

Must satisfy at least one of the following 4 criteria:

Have at least two affected relatives who are a first-degree relative to each other, of whom at least one is a first degree relative to the individual OR have at least two affected first-degree relatives on the same side of the family.

Have at least one first- or second-degree affected relative and have germline genetic test results that confirm a likely pathogenic or pathogenic variant in at least one of the following genes:

APC (Familial Adenomatous Polyposis (FAP) and Attenuated FAP syndrome

BRCA1(Hereditary Breast and Ovarian Cancer Symptoms)

MLH1, MSH2, MSH6, PMS2, or EPCAM (Lynch Syndrome)

TP53 (Li-Fraumeni Syndrome)

Other established pancreatic cancer predisposition gene per project leader's discretion

Have germline genetic test results that confirm a likely pathogenic or pathogenic variant in one or more of the following genes:

CDKN2A/p16 (Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM))

STK11 aka LKB1 (Peutz-Jeghers Syndrome)

PRSS1, SPINK1/PST1, CTRC, CPA1 or other candidate hereditary pancreatitis genes per project leader's discretion

ATM (ataxia telangiectasia mutated)

BRCA 2(Hereditary Breast and Ovarian Cancer Symptoms)

Relatives at least 21 years old with other high-risk clinical criteria that warrants pancreatic cancer surveillance or follow-up as determined the project leader (Dr. Vineet Rolston) Cohort 2 - Multiparametric endoscopic ultrasound imaging (mpEUS) of patients with pancreatic ductal adenocarcinoma: Patient Group: those with pancreatic cancer having endoscopic ultrasound-guided biopsies Patients will be entered into the study if they meet the following criteria:

Patients with pancreatic ductal adenocarcinoma

Are undergoing endoscopic ultrasound-guided tissue core biopsy as part of their standard of care

Not pregnant and not nursing Cohort 3 - Thyroid nodule assessment with multiparametric ultrasound (mpUS) imaging: Patient Group: those with a thyroid nodule that will be biopsied whether they have known cancer or not

Are undergoing ultrasound-guided thyroid biopsy as part of their standard of care

Not pregnant and not nursing Healthy Volunteers will be entered into the study if they meet the following criteria:

No known cancer diagnosis or thyroid nodules

Able to understand and give informed consent

Not pregnant and not nursing

Exclusion Criteria

Cohort 2 - Multiparametric endoscopic ultrasound imaging (mpEUS) of patients with pancreatic ductal adenocarcinoma:

Unable to sign an informed consent for medical or other reasons; residents outside the continental United States

Under 18 years of age Cohort 3 -Thyroid nodule assessment with multiparametric ultrasound (mpUS) imaging

Unable to sign an informed consent for medical or other reasons; residents outside the continental United States

Under 18 years of age

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Middletown?

Yes, this clinical trial (NCT07270237) has an active research site in Middletown, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pancreatic Cancer Treatment Options in Middletown, NJ

If you're searching for pancreatic cancer treatment options in Middletown, NJ, this clinical trial (NCT07270237) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Middletown research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pancreatic cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pancreatic cancer clinical trials near you to find additional studies recruiting in your area.

Pancreatic Cancer Clinical Trial in Middletown, NJ

Expert Care in Middletown

IRB Approved

No-Cost Care

Apply for This Middletown Location

Why Participate?

Simple Process